JP2016512505A5 - - Google Patents

Download PDF

Info

Publication number
JP2016512505A5
JP2016512505A5 JP2016500933A JP2016500933A JP2016512505A5 JP 2016512505 A5 JP2016512505 A5 JP 2016512505A5 JP 2016500933 A JP2016500933 A JP 2016500933A JP 2016500933 A JP2016500933 A JP 2016500933A JP 2016512505 A5 JP2016512505 A5 JP 2016512505A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
substituted
phenyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016500933A
Other languages
English (en)
Japanese (ja)
Other versions
JP6427551B2 (ja
JP2016512505A (ja
Filing date
Publication date
Priority claimed from US14/200,055 external-priority patent/US9050345B2/en
Application filed filed Critical
Publication of JP2016512505A publication Critical patent/JP2016512505A/ja
Publication of JP2016512505A5 publication Critical patent/JP2016512505A5/ja
Application granted granted Critical
Publication of JP6427551B2 publication Critical patent/JP6427551B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016500933A 2013-03-11 2014-03-10 カリウムイオンチャネル阻害剤としてのピロロトリアジン Expired - Fee Related JP6427551B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361775731P 2013-03-11 2013-03-11
US61/775,731 2013-03-11
US14/200,055 2014-03-07
US14/200,055 US9050345B2 (en) 2013-03-11 2014-03-07 Pyrrolotriazines as potassium ion channel inhibitors
PCT/US2014/022265 WO2014143610A1 (en) 2013-03-11 2014-03-10 Pyrrolotriazines as potassium ion channel inhibitors

Publications (3)

Publication Number Publication Date
JP2016512505A JP2016512505A (ja) 2016-04-28
JP2016512505A5 true JP2016512505A5 (enExample) 2017-04-13
JP6427551B2 JP6427551B2 (ja) 2018-11-21

Family

ID=51488539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016500933A Expired - Fee Related JP6427551B2 (ja) 2013-03-11 2014-03-10 カリウムイオンチャネル阻害剤としてのピロロトリアジン

Country Status (8)

Country Link
US (1) US9050345B2 (enExample)
EP (1) EP2970296B1 (enExample)
JP (1) JP6427551B2 (enExample)
CN (1) CN105008367B (enExample)
AR (1) AR095208A1 (enExample)
TW (1) TW201444847A (enExample)
UY (1) UY35381A (enExample)
WO (1) WO2014143610A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013274619B2 (en) * 2012-06-11 2017-09-28 Bristol-Myers Squibb Company Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide
EP2970294B1 (en) 2013-03-11 2016-12-28 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
WO2014143609A1 (en) 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
WO2014143607A1 (en) 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Pyrrolopyridazines as potassium ion channel inhibitors
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
JP2018528951A (ja) * 2015-08-31 2018-10-04 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company TGFβ受容体アンタゴニスト
CN105111154A (zh) * 2015-09-15 2015-12-02 上海瑞博化学有限公司 一种5-氨基吡嗪-2-甲酸合成新工艺
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
CN114456176B (zh) 2016-03-28 2024-08-30 因赛特公司 作为tam抑制剂的吡咯并三嗪化合物
CA3021185C (en) 2016-04-28 2024-06-04 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US11382881B2 (en) 2017-05-05 2022-07-12 Nino Sorgente Methods and compositions for diagnosing and treating glaucoma
WO2018204721A1 (en) 2017-05-05 2018-11-08 Nino Sorgente Methods and compositions for improving eye health
CA3066939A1 (en) 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
EP3898609A1 (en) 2018-12-19 2021-10-27 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CN111825675B (zh) * 2019-04-15 2023-08-01 武汉朗来科技发展有限公司 Rock抑制剂及其制备方法和用途
KR20230106648A (ko) * 2020-11-10 2023-07-13 포그혼 쎄라퓨틱스 인크. 화합물 및 그의 용도
EP4504341A1 (en) 2022-04-08 2025-02-12 Shy Therapeutics LLC Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
KR20250024923A (ko) 2022-05-11 2025-02-20 포그혼 쎄라퓨틱스 인크. 화합물 및 그의 용도
EP4610260A4 (en) * 2022-10-28 2025-11-26 Shanghai Shenshi Wise Tech Co Ltd Aryl heterocyclic kv1.3 inhibitor, preparation method therefor, and use thereof
CN116063183B (zh) * 2023-01-28 2023-06-27 山东国邦药业有限公司 一种环丙胺的合成方法
CN121941688A (zh) * 2023-10-09 2026-04-28 浙江海正药业股份有限公司 多取代芳基类衍生物及其制备方法和用途
WO2026019945A1 (en) * 2024-07-17 2026-01-22 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
WO2026025999A1 (zh) * 2024-08-01 2026-02-05 浙江海正药业股份有限公司 6,7-二氢-5H-吡咯并[1,2-a]咪唑类衍生物及其制备方法和用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
PT1094816E (pt) 1998-07-06 2009-03-10 Bristol Myers Squibb Co Sulfonamidas bifenílicas duplamente antagonistas receptores de angiotensina e endotelina
CZ303660B6 (cs) * 1999-05-21 2013-02-13 Bristol-Myers Squibb Company Pyrrolotriazin a farmaceutický prostredek s jeho obsahem
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
KR100847605B1 (ko) 2000-11-17 2008-07-21 브리스톨-마이어스스퀴브컴파니 p38 키나제 관련 질병의 치료 방법 및 키나제 억제제로서유용한 피롤로트리아진 화합물
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
WO2004013145A1 (en) 2002-08-02 2004-02-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
TW200420565A (en) * 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
MXPA05008183A (es) 2003-02-05 2005-10-05 Bristol Myers Squibb Co Proceso para preparar pirrolotriazina como inhibidores de cinasa.
US7504521B2 (en) 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
AP2007003923A0 (en) 2004-09-30 2007-02-28 Tibotec Pharm Ltd Hcv inhibiting bi-cyclic pyrimidines
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
CA2645031A1 (en) 2006-03-07 2007-09-13 Bristol-Myers Squibb Company Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
WO2007107005A1 (en) 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity
CN101511835B (zh) * 2006-07-07 2013-11-27 布里斯托尔-迈尔斯斯奎布公司 吡咯并三嗪激酶抑制剂
US7531539B2 (en) 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
EP2134716A1 (en) 2007-04-18 2009-12-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
ES2400604T3 (es) 2007-08-17 2013-04-11 Icagen, Inc. Heterociclos como moduladores del canal de potasio
DE102007051762A1 (de) * 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
CN102015719A (zh) 2008-03-06 2011-04-13 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
US20110269740A1 (en) 2008-07-02 2011-11-03 Ambit Biosciences Corporation Jak kinase modulating compounds and methods of use thereof
EP2344504B1 (en) * 2008-10-08 2014-06-04 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
ES2900504T3 (es) 2009-09-03 2022-03-17 Bristol Myers Squibb Co Quinazolinas como inhibidores de los canales iónicos de potasio
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
CN103373996A (zh) 2012-04-20 2013-10-30 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的二并环衍生物
AU2013274619B2 (en) * 2012-06-11 2017-09-28 Bristol-Myers Squibb Company Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide

Similar Documents

Publication Publication Date Title
JP2016514129A5 (enExample)
JP2016512504A5 (enExample)
JP2016516691A5 (enExample)
JP2014015465A5 (enExample)
JP2016006118A5 (enExample)
JP2015500843A5 (enExample)
JP2016534134A5 (enExample)
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
JP2013537203A5 (enExample)
JP2014530900A5 (enExample)
JP2016517417A5 (enExample)
JP2016531126A5 (enExample)
JP2016506960A5 (enExample)
JP2017517538A5 (enExample)
JP2020527175A5 (enExample)
JP2014506907A5 (enExample)
JP2016500661A5 (enExample)
JP2016528273A5 (enExample)
JP2017514855A5 (enExample)
JP2012532112A5 (enExample)
JP2016515560A5 (enExample)
RU2016115487A (ru) Тиазолопиримидиноны в качестве модуляторов активности рецепторов nmda
JP2017537937A5 (enExample)
JP2013527847A5 (enExample)
JP2015500223A5 (enExample)